Q1 Earnings Estimate for Arcus Biosciences Issued By Wedbush

Arcus Biosciences, Inc. (NYSE:RCUS) – Stock analysts at Wedbush increased their Q1 2025 earnings per share estimates for shares of Arcus Biosciences in a research report issued to clients and investors on Tuesday, February 25th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($1.08) per share for the quarter, up from their prior estimate of ($1.31). Wedbush has a “Outperform” rating and a $36.00 price objective on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Wedbush also issued estimates for Arcus Biosciences’ Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.03) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($4.16) EPS, FY2026 earnings at ($3.93) EPS, FY2027 earnings at ($3.24) EPS, FY2028 earnings at ($0.18) EPS and FY2029 earnings at $3.71 EPS.

Several other brokerages have also recently commented on RCUS. HC Wainwright raised Arcus Biosciences from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $18.00 to $24.00 in a report on Wednesday. Bank of America dropped their price objective on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. Finally, Morgan Stanley decreased their target price on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $30.25.

Arcus Biosciences Trading Down 2.7 %

Shares of NYSE:RCUS opened at $9.87 on Friday. The company has a 50 day moving average of $13.46 and a 200-day moving average of $15.42. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. The firm has a market cap of $1.04 billion, a P/E ratio of -3.13 and a beta of 0.84. Arcus Biosciences has a twelve month low of $9.85 and a twelve month high of $20.10.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.17) by $0.14. The business had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%.

Institutional Trading of Arcus Biosciences

Hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP raised its position in Arcus Biosciences by 17.8% during the third quarter. GSA Capital Partners LLP now owns 187,415 shares of the company’s stock valued at $2,866,000 after buying an additional 28,307 shares during the period. Quest Partners LLC grew its stake in Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after acquiring an additional 9,408 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Arcus Biosciences by 25.1% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock valued at $14,236,000 after purchasing an additional 186,750 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Arcus Biosciences in the third quarter worth approximately $244,000. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Arcus Biosciences by 39.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 80,889 shares of the company’s stock worth $1,237,000 after purchasing an additional 22,716 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Insider Buying and Selling

In other news, CEO Terry J. Rosen purchased 19,800 shares of Arcus Biosciences stock in a transaction that occurred on Thursday, February 27th. The stock was acquired at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the transaction, the chief executive officer now owns 2,554,160 shares in the company, valued at $26,001,348.80. The trade was a 0.78 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Yasunori Kaneko acquired 20,000 shares of the stock in a transaction on Thursday, February 27th. The shares were purchased at an average price of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the transaction, the director now owns 28,400 shares in the company, valued at approximately $285,704. This represents a 238.10 % increase in their position. The disclosure for this purchase can be found here. Insiders own 12.30% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.